Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

British Journal of Cancer

Volumn 113, Issue 11, 2015, Pages 1571-1580

  Donskov, Frede ^a   Michaelson, M Dror ^b   Puzanov, Igor ^c   Davis, Mellar P ^d   Bjarnason, Georg A ^e   Motzer, Robert J ^f   Goldstein, David ^g   Lin, Xun ^h   Cohen, Darrel P ^h   Wiltshire, Robin ⁱ   Rini, Brian I ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h PFIZER INC   (United States)

ⁱ PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

adverse events; biomarkers; hypertension; metastatic renal cell carcinoma; multivariate; neutropenia; sunitinib

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ADULT; ARTICLE; ASTHENIA; BLOOD PRESSURE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER STAGING; DIASTOLIC BLOOD PRESSURE; FEMALE; GOOD CLINICAL PRACTICE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; AGED; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; FATIGUE; HAND-FOOT SYNDROME; KIDNEY NEOPLASMS; PATHOLOGY; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; HAND-FOOT SYNDROME; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PYRROLES; SURVIVAL RATE; YOUNG ADULT;

EID: 84949316180     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.368     Document Type: Article

References (43)

1. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY. (2012). Phase II trial of continuous once-daily dosing of sunitinib as firstline treatment in patients with metastatic renal cell carcinoma. Cancer 118: 1252-1259.
2. Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ, Powles T. (2014). Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol 65: 766-777.
3. Carus A, Gurney H, Gebski V, Harnett P, Hui R, Kefford R, Wilcken N, Ladekarl M, von der Maase H, Donskov F. (2013). Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 11: 189.
4. Dechend R, Luft FC. (2008). Angiogenesis factors and preeclampsia. Nature Med 14: 1187-1188.
5. Dienstmann R, Bran'a I, Rodon J, Tabernero J. (2011). Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16: 1729-1740.
6. Donskov F. (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 23: 200-207.
7. Dumitru CA, Lang S, Brandau S. (2013). Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol 23: 141-148.
8. Escudier B, Loomis AK, Kaprin A, Motzer R, Tomczak P, Tarazi J, Kim S, Gao F, Williams JA, Rini B. (2011). Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib vs sorafenib (AXIS trial). In: European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical Oncology, Advocacy and Care. Eur J Cancer 47: S505 (abstract 7103
9. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. (2009). Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4068-4075.
10. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiel A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. (2009). Analysis of PTEN and HIF1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-Alpha. Cancer 115: 3651-3660.
11. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martinez E, Moreno F, Font A, Robledo M, Rodriguez-Antona C. (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal cell carcinoma treated with firstline sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143-1150.
12. Gurney H. (2002). How to calculate the dose of chemotherapy. Br J Cancer 86: 1297-1302.
13. Harmon CS, Deprimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ. (2014). Circulating proteins as potential biomarkers of sunitinib and interferon-A efficacy in treatment-naive patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 73: 151-161.
14. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Dargeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799.
15. HengDY, XieW, ReganMM, Harshman LC, Bjarnason GA, VaishampayanUN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14: 141-148.
16. Hood JD, Meininger CJ, Ziche M, Granger HJ. (1998). VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274: H1054-H1058.
17. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. (2009). Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338.
18. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. (2009). Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 27: 4709-4717.
19. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16: 293-300.
20. Kumar R, Crouthamel M-C, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG. (2009). Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101: 1717-1723.
21. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. on behalf of the European Association of Urology Guideline Group. (2010). European Association of Urology (EAU
22. Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406.
23. Mains JR, Donskov F, Pedersen EM, Madsen HH, Rasmussen F. (2014). Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1. Invest Radiol 49: 601-607.
24. Motzer RJ, Agarwal N, Beard C. (2011). National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Kidney Cancer, version 1.2011. Available at www.NCCN.org/professionals/physician-gls/PDF/kidney.pdf (accessed 5 January 2011
25. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. (2002). Interferon-Alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296.
26. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
27. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
28. Motzer RJ, Rini BI, Bukowski RM, Curti BD, GeorgeDJ, HudesGR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524.
29. Muriel Lopez C, Esteban E, Astudillo A, Pardo P, Berros JP, Izquierdo M, Crespo G, Fonseca PJ, Sanmamed M, Martinez-Camblor P. (2012). Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 30: 2443-2449.
30. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ. (2011). Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22: 295-300.
31. Pen'a C, Lathia C, Shan M, Escudier B, Bukowski RM. (2010). Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 16: 4853-4863.
32. Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P. (2014). Sunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patients. BJU Int; e-pub ahead of print 23 September 2014; doi:10.1111/bju.12940.
33. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ. (2011). Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773.
34. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC. (2011). Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117: 534-544.
35. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. on behalf of ECOG 2100. (2008). Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26: 4672-4678Erratum in: J Clin Oncol. (2009). 27: 3070.
36. Soerensen AV, Geertsen PF, Christensen IJ, Hermann GG, Jensen NV, Fode K, Petersen A, Sandin R, Donskov F. (2015). A 5-factor biomarker profile obtained week 4 to 12 of treatment for improved prognostication in metastatic renal cell carcinoma: results from DARENCA study 2. Acta Oncol; e-pub ahead of print 8 October 2015.
37. Sunitinib malate (SUTENT) prescribing information. (2014). Revised 08/13. Available at http://www.sutent.com (accessed 30 January 2014
38. Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E. (1997). Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol 62: 397-400.
39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
40. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. (2012). Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13: 827-837.
41. Van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. (2007). Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25: 2993-2995.
42. Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, de Souza P, Xue ZG, McCann L, King KS, Ragone LJ, Whittaker JC, Spraggs CF, Cardon LR, Mooser VE, Pandite LN. (2011). Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 29: 2557-2564.
43. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. (2012). A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23: 46-52.